Skip to content
Head to head

Genmab vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: GMAB · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

GMAB +66.3%VRTX +18.7%
It’s close.
GMABVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price50.60515.02
Change today-1.46%-1.08%
1-year return+68.4%+22.0%
Market cap$31.20B$130.58B
52-week range23.62 – 59.97412.27 – 568.67
Valuation
P/E (TTM)43.2533.14
P/E percentile, own 5-yr range81st99th
P/B4.936.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)1.5415.32
Net profit (TTM)$947.70M$3.88B
Revenue (TTM)$4.30B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+16.1%+11.8%
Gross margin92.7%85.5%
Operating margin30.6%33.1%
Net margin17.0%30.7%
Free cash flow (TTM)$843.00M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership61.6%96.8%
Insider activity (12mo)0 buy / 3 sell28 buy / 22 sell
Short interest (% of float)1.6%1.9%
Analyst consensus89% buy / 11% hold (9)95% buy / 5% hold (21)
Analyst price target$65 (+28%)$624 (+21%)
StockVane view
StockVane Quant RatingC (92)C (68)
Company
Employees2,8196,400
Founded19981989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.